CRC Research Update — October 30, 2026
Today's colorectal cancer research highlights
msi-h
A collection of 131 issues
New predictive model identifies mismatch repair deficiency in resource-limited settings
Skip to content
The CRC Digest
New predictive model identifies mismatch repair deficiency in resource-limited settings
Cross-sectional analysis of 185 Sri Lankan patients found 12.4% were mismatch repair deficient; multivariable analysis identified age under 60, right-sided tumors, family history, and specific histologic features as significant predictors. (BMC Cancer)
This
CRC Research Update — October 28, 2026
Today's colorectal cancer research highlights
WRN helicase emerges as therapeutic target in MSI-H colorectal cancer
Skip to content
The CRC Digest
WRN helicase emerges as therapeutic target in MSI-H colorectal cancer
MSI-H and mismatch repair-deficient cancers show dependence on Werner syndrome RecQ helicase (WRN), a synthetic-lethal vulnerability linked to expanded TA-dinucleotide repeats and replication-associated genome instability, though dependency is not universal among all MSI-H tumors.
CRC Research Update — October 25, 2026
Today's colorectal cancer research highlights
Molecular profiling study identifies clinicopathological factors linked to dMMR/MSI-H status
Skip to content
The CRC Digest
Molecular profiling study identifies clinicopathological factors linked to dMMR/MSI-H status
In 272 resected colorectal cancers, dMMR/MSI-H was present in 9.6% of tumors and independently associated with younger age, proximal tumor location, and poor differentiation. (Clinical Therapeutics)
This content is informational only
Final CheckMate 8HW results show survival benefit with nivolumab plus ipilimumab in MSI-H/dMMR metastatic colorectal cancer
Skip to content
The CRC Digest
◆ TRIAL DATA
Final CheckMate 8HW results show survival benefit with nivolumab plus ipilimumab in MSI-H/dMMR metastatic colorectal cancer
At 68 months median follow-up, the phase III trial demonstrated significant overall survival benefit with nivolumab plus ipilimumab versus nivolumab alone across all treatment lines
FDA grants accelerated approval for dostarlimab in locally advanced rectal cancer with dMMR tumors
Skip to content
The CRC Digest
● REGULATORY
FDA grants accelerated approval for dostarlimab in locally advanced rectal cancer with dMMR tumors
The immunotherapy Jemperli (dostarlimab-gxly) received accelerated approval for previously untreated stage II or III locally advanced rectal cancer with mismatch repair deficient tumors, potentially allowing some patients to avoid
CRC Research Update — October 22, 2026
Today's colorectal cancer research highlights
Maintenance immunotherapy after complete response may not be necessary in dMMR/MSI-H rectal cancer
Skip to content
The CRC Digest
◆ TRIAL DATA
Maintenance immunotherapy after complete response may not be necessary in dMMR/MSI-H rectal cancer
A multicenter cohort study of 129 patients who entered non-operative management after achieving clinical complete response with PD-1 inhibitors found 3-year disease-free survival was 96.2% with observation